Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Shares Outstanding (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Shares Outstanding for 2 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 38.62% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 38.62% year-over-year, with the annual reading at $4.5 million for FY2025, 38.62% up from the prior year.
  • Shares Outstanding hit $4.5 million in Q4 2025 for Xilio Therapeutics, down from $51.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $51.8 million in Q3 2025 to a low of $3.3 million in Q4 2024.